Email ID
Password
Scrip   
United Therapeutics' inhaled PAH treatment approved in US
03 August 2009
Katie McQue

The US FDA has approved United Therapeutics' inhaled formulation of treprostinil, Tyvaso, for the treatment of pulmonary arterial hypertension (PAH).

Tyvaso is indicated to increase walk distance in patients with NYHA Class III symptoms – which correspond to a marked limitation of...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36